Ardelyx Trying To Rewrite Tenapanor’s Narrative: Less Side Effects, New Biomarker

15 Jul 2015

Having regained full rights to the first-in-class NHE3 inhibitor from AstraZeneca, Ardelyx plans a Phase III study in IBS-C and a Phase IIb study in hyperphosphatasia related to kidney dialysis before year’s end.

Roughly six weeks after regaining rights to first-in-class NHE3 inhibitor tenapanor from AstraZeneca PLC, Ardelyx Inc. is planning a Phase IIb study in hyperphosphatasia where it hopes to show lower doses can sufficiently reduce serum phosphate levels while minimizing adverse events that led to treatment discontinuations in a prior Phase IIb trial.

During its investor day presentation July 14, the Fremont, Calif.-based company outlined plans for that program as well for Phase...